| Q41030957 | A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. |
| Q33840502 | Accessory molecules for MHC class II peptide loading |
| Q34303158 | Accessory proteins that control the assembly of MHC molecules with peptides. |
| Q28510157 | Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice |
| Q38874605 | Antigen Processing and Presentation Mechanisms in Myeloid Cells |
| Q34011098 | Antigen-processing machinery breakdown and tumor growth |
| Q64913188 | B Cell-Based Cancer Immunotherapy. |
| Q34540061 | Binding interactions between peptides and proteins of the class II major histocompatibility complex |
| Q47580877 | Biochemical pathway of antigen processing by HLA class II molecules in B cell lymphomas |
| Q40910547 | C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells |
| Q30384608 | CD4+ T-cell epitope prediction using antigen processing constraints |
| Q38113268 | CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application |
| Q40970107 | Cellular distribution of a mixed MHC class II heterodimer between DRalpha and a chimeric DObeta chain |
| Q36083424 | Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis |
| Q93020630 | Class II MHC antigen processing in immune tolerance and inflammation |
| Q40682274 | Class II transactivator-induced expression of HLA-DO(beta) in HeLa cells |
| Q36396787 | Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes |
| Q38050482 | Conformational variation in structures of classical and non-classical MHCII proteins and functional implications |
| Q38701681 | Conservation of MHC class II DOA sequences among carnivores |
| Q40990619 | Conserved structural features between HLA-DO beta and -DR beta |
| Q27640503 | Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif |
| Q27765681 | Crystal structure of mouse H2-M |
| Q39712353 | DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms |
| Q36369018 | Dynamic tuning of T cell reactivity by self-peptide-major histocompatibility complex ligands |
| Q82661832 | Evidence for a human leucocyte antigen-DM-induced structural change in human leucocyte antigen-DObeta |
| Q28084268 | Exogenous antigens bind MHC class II first, and are processed by cathepsins later |
| Q43802418 | Functional analysis of tryptophans alpha 62 and beta 120 on HLA-DM. |
| Q74241727 | Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DObeta |
| Q40737770 | Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO. |
| Q34151755 | H2-O, a MHC class II-like protein, sets a threshold for B-cell entry into germinal centers |
| Q28143818 | HLA-DM - an endosomal and lysosomal chaperone for the immune system |
| Q38181859 | HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation |
| Q36404572 | HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. |
| Q34492989 | HLA-DM, HLA-DO and tapasin: functional similarities and differences |
| Q90681131 | HLA-DO Modulates the Diversity of the MHC-II Self-peptidome |
| Q27675409 | HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism |
| Q38134729 | HLA-DO and Its Role in MHC Class II Antigen Presentation. |
| Q34948997 | HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation |
| Q74578843 | Human epidermal Langerhans cells lack functional mannose receptors and a fully developed endosomal/lysosomal compartment for loading of HLA class II molecules |
| Q26741035 | Human leukocyte Antigen-DM polymorphisms in autoimmune diseases |
| Q34722781 | IgE-mediated enhancement of antibody responses: the beneficial function of IgE? |
| Q74595052 | Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice |
| Q61960529 | Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator |
| Q38175028 | Inhibition of HLA-DM Mediated MHC Class II Peptide Loading by HLA-DO Promotes Self Tolerance |
| Q33815425 | Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors |
| Q39427560 | Introduction: MHC/KIR and governance of specificity |
| Q45739949 | Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation |
| Q37189146 | MHC class II antigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes |
| Q38167996 | MHC class II antigen presentation by dendritic cells regulated through endosomal sorting |
| Q33957690 | MHC class II-restricted antigen processing and presentation |
| Q38390459 | MHC structure and function - antigen presentation. Part 2 |
| Q48263494 | Major histocompatibility complex class II DOA sequences from three Antarctic seal species verify stabilizing selection on the DO locus |
| Q24338938 | Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis |
| Q42944165 | Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. |
| Q35119884 | Molecular Mechanisms of B Cell Antigen Receptor Trafficking |
| Q34586106 | Molecular mechanisms of nanosized titanium dioxide-induced pulmonary injury in mice |
| Q40081254 | Neutralizing Antibody Responses to Viral Infections Are Linked to the Non-classical MHC Class II Gene H2-Ob. |
| Q39957670 | Oxidative stress impairs intracellular events involved in antigen processing and presentation to T cells |
| Q33631854 | Pathways of antigen processing |
| Q33815435 | Peptide exchange in MHC molecules |
| Q33683408 | Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses |
| Q34156238 | Phagocytic processing of antigens for presentation by class II major histocompatibility complex molecules |
| Q35942429 | Presentation of cytosolic antigens via MHC class II molecules |
| Q24290905 | Protein kinase D regulates the fission of cell surface destined transport carriers from the trans-Golgi network |
| Q33885986 | Proteolysis in MHC class II antigen presentation: who's in charge? |
| Q36370114 | Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development |
| Q36266508 | Right place, right time, right peptide: DO keeps DM focused |
| Q46972584 | Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM. |
| Q67849296 | Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function |
| Q52543788 | Stat3 in thymic epithelial cells is essential for postnatal maintenance of thymic architecture and thymocyte survival. |
| Q90288626 | Synergy between B cell receptor/antigen uptake and MHCII peptide editing relies on HLA-DO tuning |
| Q38625770 | TLR agonists downregulate H2-O in CD8alpha- dendritic cells |
| Q28589559 | Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions |
| Q33755350 | Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence |
| Q48272625 | The HLA-DOB gene displays limited polymorphism with only one amino acid substitution |
| Q34129320 | The control and facilitation of MHC class II antigen processing by the BCR. |
| Q35821240 | The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules |
| Q35794597 | The expression of HLA-DO (H2-O) in B lymphocytes |
| Q28142443 | The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules |
| Q35785432 | The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway |
| Q85034619 | The prolonged and enhanced immune response in the non-obese diabetic mouse is dependent on genes in the Idd1/24, Idd12 and Idd18 regions |
| Q33815445 | The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation |
| Q27765680 | The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation |
| Q33736024 | Thiol oxidation and reduction in MHC-restricted antigen processing and presentation. |
| Q77298530 | Trafficking of the Igalpha/Igbeta heterodimer with membrane Ig and bound antigen to the major histocompatibility complex class II peptide-loading compartment |
| Q36848435 | Ubiquitination of HLA-DO by MARCH family E3 ligases |
| Q36323798 | pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity |